We are a global, full-service contract research organization (CRO), the only one focused exclusively on central nervous system (CNS) drug development, an area of significant unmet need. We are dedicated to bringing new therapies to patients living with mental health, neurological, and substance abuse disorders. Clinilabs partners with our customers to deliver a full, first-in-human to Phase 3 spectrum of high quality, timely, and cost-effective clinical drug development services, with the shared goal of speeding new CNS medicines to market. At Clinilabs, experience, scientific knowledge, and operational expertise combine with accountability, responsibility, and integrity to create a powerful value proposition for the pharma and biotech companies we serve. We are process-driven yet structured to be nimble, providing personalized service to customers of all sizes for projects of all scope. Clinilabs has conducted more than 675 CNS clinical trials and played a pivotal role in the approval of 19 new therapies in 10 different indications to help transform the lives of patients.
There is so much more to be done; the patients are waiting.
– Dr. Paul Janssen
We empower study participants through informed decisions regarding study participation.
Clinilabs offers a full range of Phase I, II and III clinical development services.